Should the statin and fibrate be discontinued before an acute cholecystectomy?

Perioperative Management of Statins and Fibrates for Acute Cholecystectomy

Continue statins perioperatively and do not discontinue them before acute cholecystectomy; fibrates should be temporarily withheld during the perioperative period due to increased risk of myopathy and renal complications.

Statin Management

Statins must be continued throughout the perioperative period 1. The 2014 ACC/AHA perioperative guidelines provide a Class I, Level B recommendation to continue statins in patients currently taking them 1. This is not optional—discontinuing statins perioperatively is associated with worse cardiac outcomes and a rebound inflammatory surge that increases morbidity 2.

Key Evidence for Statin Continuation:

• Statins attenuate perioperative inflammation and improve cardiac outcomes 3
• Withdrawal after surgery causes an inflammatory rebound with adverse cardiac events 2
• The protective effects are lost when statins are discontinued, even briefly 3

Practical Implementation:

• Do not hold statins on the day of surgery or any perioperative day
• If the patient cannot take oral medications postoperatively (e.g., ileus), resume statins as soon as oral intake is feasible 2
• This applies to both elective and acute cholecystectomy

Fibrate Management

Fibrates should be temporarily discontinued during the perioperative period, particularly around major surgery 4. The 2002 ACC/AHA/NHLBI advisory specifically identifies the perioperative period as an increased risk state for statin-associated myopathy, and notes that myopathy has developed when patients continued on statin therapy during hospitalization for major surgery 4.

Rationale for Fibrate Discontinuation:

• Fibrates (especially gemfibrozil) significantly increase the risk of myopathy when combined with statins 4, 5
• The perioperative period is explicitly listed as a high-risk state for statin-fibrate myopathy 4
• Renal function may be more commonly affected with fibrate use, either alone or in combination with statins 5
• The combination carries higher risk than statin monotherapy, particularly in patients with multisystem disease or multiple medications 4

Clinical Context:

While fibrates alone may reduce gallstone risk with long-term use 6, this potential benefit is irrelevant in the acute cholecystectomy setting where the gallbladder is being removed. The immediate perioperative myopathy and renal risks outweigh any theoretical benefit.

Common Pitfalls to Avoid

• Do not discontinue statins thinking you're reducing surgical risk—you're actually increasing cardiac risk 2
• Do not continue fibrates assuming they're as safe as statins perioperatively—they're not 4
• Do not forget to restart fibrates postoperatively once the patient is stable and oral intake is established
• Monitor for muscle symptoms (soreness, tenderness, pain) and check CK levels if symptoms develop 4

Algorithm for Decision-Making

1. Patient on statin alone: Continue through surgery
2. Patient on fibrate alone: Hold perioperatively, restart postoperatively when stable
3. Patient on statin + fibrate combination: Continue statin, hold fibrate perioperatively
4. If patient develops muscle symptoms: Check CK and thyroid function; discontinue both if CK >10× upper limit of normal with symptoms 4

The evidence strongly supports maintaining cardiovascular protection with statins while temporarily reducing myopathy risk by holding fibrates during the acute perioperative window.